PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer

The therapeutic HER2-targeting antibody trastuzumab has been shown to elicit tumor immune response in a subset of HER2-positive (HER2+) breast cancer. We performed genomic and immunohistochemical profiling of tumors from eight patients who have completed multiple rounds of neoadjuvant trastuzumabb t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendricks, William P. D., Briones, Natalia, Halperin, Rebecca F., Facista, Salvatore, Heaton, Paul R., Mahadevan, Daruka, Kim, Suwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826891/
https://www.ncbi.nlm.nih.gov/pubmed/31618954
http://dx.doi.org/10.3390/cancers11101566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826891/
https://www.ncbi.nlm.nih.gov/pubmed/31618954
http://dx.doi.org/10.3390/cancers11101566

Ejemplares similares